174 related articles for article (PubMed ID: 26274622)
1. The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy).
Vivekanandan S; Breene R; Ramanujachar R; Traunecker H; Pizer B; Gaze MN; Saran F; Thorp N; English M; Wheeler KA; Michalski A; Walker DA; Saunders D; Cowie F; Cameron A; Picton SV; Parashar D; Horan G; Williams MV
Pediatr Blood Cancer; 2015 Dec; 62(12):2132-9. PubMed ID: 26274622
[TBL] [Abstract][Full Text] [Related]
2. Comment on: The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy, and Response Directed High-Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy).
Massimino M; Spreafico F; Pignoli E; Gandola L
Pediatr Blood Cancer; 2016 Jun; 63(6):1123-4. PubMed ID: 26766787
[No Abstract] [Full Text] [Related]
3. Reply to Comment on: The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy, and Response-Directed High-Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy).
Vivekanandan S; Breene R; Ramanujachar R; Traunecker H; Pizer B; Gaze MN; Saran F; Thorp N; English M; Wheeler K; Michalski A; Walker DA; Saunders D; Cowie F; Cameron A; Picton S; Parashar D; Horan G; Williams MV
Pediatr Blood Cancer; 2016 Jun; 63(6):1125-6. PubMed ID: 26891280
[No Abstract] [Full Text] [Related]
4. Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol.
von Bueren AO; Friedrich C; von Hoff K; Kwiecien R; Müller K; Pietsch T; Warmuth-Metz M; Hau P; Benesch M; Kuehl J; Kortmann RD; Rutkowski S
Eur J Cancer; 2015 Nov; 51(16):2434-43. PubMed ID: 26254812
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma.
Gandola L; Massimino M; Cefalo G; Solero C; Spreafico F; Pecori E; Riva D; Collini P; Pignoli E; Giangaspero F; Luksch R; Berretta S; Poggi G; Biassoni V; Ferrari A; Pollo B; Favre C; Sardi I; Terenziani M; Fossati-Bellani F
J Clin Oncol; 2009 Feb; 27(4):566-71. PubMed ID: 19075266
[TBL] [Abstract][Full Text] [Related]
6. Local control in non-metastatic medulloblastoma.
Christopherson KM; Bradley JA; Rotondo RL; Pincus DW; Fort JA; Morris CG; Mendenhall NP; Marcus RB; Indelicato DJ
Acta Oncol; 2014 Sep; 53(9):1151-7. PubMed ID: 24991891
[TBL] [Abstract][Full Text] [Related]
7. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?
Dupuis-Girod S; Hartmann O; Benhamou E; Doz F; Mechinaud F; Bouffet E; Coze C; Kalifa C
J Neurooncol; 1996 Jan; 27(1):87-98. PubMed ID: 8699230
[TBL] [Abstract][Full Text] [Related]
8. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
[TBL] [Abstract][Full Text] [Related]
10. Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility study.
Taylor RE; Howman AJ; Wheatley K; Brogden EE; Large B; Gibson MJ; Robson K; Mitra D; Saran F; Michalski A; Pizer BL
Radiother Oncol; 2014 Apr; 111(1):41-6. PubMed ID: 24630538
[TBL] [Abstract][Full Text] [Related]
11. [High-dose chemotherapy in relapse of medulloblastoma in young children].
Dupuis-Girod S; Hartmann O; Benhamou E; Doz F; Mechinaud F; Bouffet E; Coze C; Kalifa C
Bull Cancer; 1997 Mar; 84(3):264-72. PubMed ID: 9207872
[TBL] [Abstract][Full Text] [Related]
12. [Pediatric medulloblastoma: Retrospective series of 52 patients].
Vigneron C; Antoni D; Coca A; Entz-Werlé N; Lutz P; Spiegel A; Jannier S; Niederst C; Jarnet D; Meyer P; Kehrli P; Noël G
Cancer Radiother; 2016 Apr; 20(2):104-8. PubMed ID: 26996790
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea.
Yoon JH; Park KD; Kang HJ; Kim H; Lee JW; Kim SK; Wang KC; Park SH; Kim IH; Shin HY
World J Pediatr; 2017 Aug; 13(4):367-373. PubMed ID: 28550392
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
von Bueren AO; Kortmann RD; von Hoff K; Friedrich C; Mynarek M; Müller K; Goschzik T; Zur Mühlen A; Gerber N; Warmuth-Metz M; Soerensen N; Deinlein F; Benesch M; Zwiener I; Kwiecien R; Faldum A; Bode U; Fleischhack G; Hovestadt V; Kool M; Jones D; Northcott P; Kuehl J; Pfister S; Pietsch T; Rutkowski S
J Clin Oncol; 2016 Dec; 34(34):4151-4160. PubMed ID: 27863192
[TBL] [Abstract][Full Text] [Related]
15. [Adult medulloblastoma: Retrospective series of 21 patients].
Vigneron C; Antoni D; Coca A; Niederst C; Jarnet D; Meyer P; Kehrli P; Noël G
Cancer Radiother; 2016 Feb; 20(1):14-7. PubMed ID: 26706607
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastoma: conventional radiation therapy in comparison to chemo radiation therapy in the post-operative treatment of high-risk patients.
Abd El-Aal HH; Mokhtar MM; Habib E; El-Kashef AT; Fahmy ES
J Egypt Natl Canc Inst; 2005 Dec; 17(4):301-7. PubMed ID: 17102823
[TBL] [Abstract][Full Text] [Related]
17. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols.
Dhall G; Grodman H; Ji L; Sands S; Gardner S; Dunkel IJ; McCowage GB; Diez B; Allen JC; Gopalan A; Cornelius AS; Termuhlen A; Abromowitch M; Sposto R; Finlay JL
Pediatr Blood Cancer; 2008 Jun; 50(6):1169-75. PubMed ID: 18293379
[TBL] [Abstract][Full Text] [Related]
18. A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group.
Esbenshade AJ; Kocak M; Hershon L; Rousseau P; Decarie JC; Shaw S; Burger P; Friedman HS; Gajjar A; Moghrabi A
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 28000417
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy and adjuvant chemotherapy for childhood medulloblastoma. The Royal Marsden Hospital experience.
Whitton AC; Syndikus I; Tait DM; Bloom HJ
Strahlenther Onkol; 1995 Nov; 171(11):615-21. PubMed ID: 7502224
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and abandonment and outcome of treatment in 67 Chinese children with medulloblastoma.
Wang C; Yuan XJ; Jiang MW; Wang LF
J Neurosurg Pediatr; 2016 Jan; 17(1):49-56. PubMed ID: 26451721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
